【美泊利单抗Nucala(Mepolizumab)适应症】 (1)适用于表现型为嗜伊红性白血球的严重气喘且控制不良(severe refractory eosinophilic asthma)之成人患者之附加维持治疗。 (2)使用限制: 美泊利单抗Nucala不可使用于治疗其他嗜伊红性白血病疾病。 美泊利单抗Nucala不可使用于缓解急性支气管痉挛或气喘重积状态(status asthmaticus)...
Drug class: interleukin inhibitors Breastfeeding En español Professional resources Nucala prescribing information Mepolizumab (AHFS Monograph) Related treatment guides Chronic Rhinosinusitis With Nasal Polyps Hypereosinophilic Syndrome Asthma, Maintenance Eosinophilic Granulomatosis with Polyangiitis AsthmaFurther infor...
Ref. GSK's asthma drug Nucala meets main goal in study on treating smoker's lungs. Reuters. 06. 09. 2024. McConaghie, A. ravo At Last For GSK As MATINEE Succeeds In COPD. Scrip. 06. 09. 2024.
Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.J Allergy Clin Immunol. 2019;143(5):1742-1751.e7. Felarca AB, Lowell FC. The total eosinophil count in a nonatopic popula...
Discover NUCALA (mepolizumab), an add-on maintenance treatment for patients 6+ with severe eosinophilic asthma, through efficacy data, patient profiles, and more.
美泊利单抗(NUCALA/MEPOLIZUMAB)是一种针对IL-5的人源化单克隆抗体,被批准用于治疗高嗜酸性粒细胞哮喘(eosinophilic asthma)。IL-5是导致嗜酸性粒细胞增多和激活的重要因子,而嗜酸性粒细胞增多被认为是哮喘发作和持续的主要原因之一。因此,通过抑制IL-5,美泊利单抗有可能减少哮喘症状的严重程度和频率。
“This approval offers patients with severe asthma an additional therapy when current treatments cannot maintain adequate control of their asthma,” said Badrul Chowdhury, M.D., Ph.D., director of the Division of Pulmonary, Allergy, and Rheumatology Products in the FDA’s Center for Drug Evaluati...
(1)适用于表现型为嗜伊红性白血球的严重气喘且控制不良(severe refractory eosinophilic asthma)之成人患者之附加维持治疗。 (2)使用限制: 美泊利单抗Nucala不可使用于治疗其他嗜伊红性白血病疾病。 美泊利单抗Nucala不可使用于缓解急性支气管痉挛或气喘重积状态(status asthmaticus)。
Acute Asthma Symptoms or Deteriorating Disease NUCALA should not be used to treat acute asthma symptoms, acute exacerbations, or acute bronchospasm. Opportunistic Infections: Herpes Zoster Herpes zoster infections have occurred in patients receiving NUCALA. Consider vaccination if medically appropriate. ...
Learn about the anti-IL-5 mechanism of action of NUCALA (mepolizumab) and discover how it works to target eosinophils in patients with severe eosinophilic asthma.